Cargando…

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

BACKGROUND: Our previous survey on first-in-human trials (FIHT) of monoclonal antibodies (mAbs) showed that, due to their limited toxicity, the recommended phase II dose (RP2D) was only tentatively defined. METHODS: We identified, by MEDLINE search, articles on single-agent trials of mAbs with an FI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viala, Marie, Vinches, Marie, Alexandre, Marie, Mollevi, Caroline, Durigova, Anna, Hayaoui, Nadia, Homicsko, Krisztian, Cuenant, Alice, Gongora, Céline, Gianni, Luca, Tosi, Diego
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846071/ https://www.ncbi.nlm.nih.gov/pubmed/29438365 http://dx.doi.org/10.1038/bjc.2017.473

Ejemplares similares

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents
por: Chatelut, E, et al.
Publicado: (2012)

Overestimation of carboplatin doses is avoided by radionuclide GFR measurement
por: Craig, A J, et al.
Publicado: (2012)

Embracing model-based designs for dose-finding trials
por: Love, Sharon B, et al.
Publicado: (2017)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells
por: González, A, et al.
Publicado: (2007)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer
por: Janssen, A, et al.
Publicado: (2017)

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy
por: Hudson, R, et al.
Publicado: (2005)

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
por: Boven, E, et al.
Publicado: (2010)

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
por: Michlmayr, A, et al.
Publicado: (2010)

Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours
por: Zucali, P A, et al.
Publicado: (2013)

Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model
por: Thies, A, et al.
Publicado: (2008)

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
por: Atmaca, A, et al.
Publicado: (2007)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
por: Schiffmann, L M, et al.
Publicado: (2017)

Bone marrow-derived mesenchymal stromal cells promote colorectal cancer cell death under low-dose irradiation
por: Feng, Hao, et al.
Publicado: (2018)

FAT1: a potential target for monoclonal antibody therapy in colon cancer
por: Pileri, Piero, et al.
Publicado: (2016)

Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid
por: Niedre, M J, et al.
Publicado: (2005)

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets
por: Wattenberg, M M, et al.
Publicado: (2014)

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
por: Lam, Siu W, et al.
Publicado: (2016)

Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies
por: Alvi, Muhammad A, et al.
Publicado: (2017)

Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies
por: Diaz Miqueli, A, et al.
Publicado: (2009)

Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours
por: Ahlskog, J K J, et al.
Publicado: (2009)

Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy
por: Xue, H, et al.
Publicado: (2009)

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
por: Caiazza, F, et al.
Publicado: (2015)

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer
por: Marzi, L, et al.
Publicado: (2016)

Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer
por: Royer, B, et al.
Publicado: (2010)

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
por: Marmorino, Federica, et al.
Publicado: (2017)

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
por: Panousis, C, et al.
Publicado: (2005)

Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen
por: Conaghan, P J, et al.
Publicado: (2008)

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
por: Pukac, L, et al.
Publicado: (2005)

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors
por: Fischel, J-L, et al.
Publicado: (2005)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
por: Akashi, Y, et al.
Publicado: (2008)

Interplay between cadherins and α2β1 integrin differentially regulates melanoma cell invasion
por: Siret, Carole, et al.
Publicado: (2015)

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
por: Legrier, Marie-Emmanuelle, et al.
Publicado: (2016)

Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy
por: de Graaff, Marieke A, et al.
Publicado: (2016)

H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma
por: Zhang, Wenyan, et al.
Publicado: (2018)

Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma
por: Dantas-Barbosa, Carmela, et al.
Publicado: (2017)

Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer
por: Beale, Gary, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_anll13ktv1er5ak0ubbrp1pfkn